BioLight signs joint financing agreement with two Asia-based venture capital firms

November 25, 2015

BioLight Life Sciences Investments, a company focused primarily on the discovery, development and commercialization of breakthrough ophthalmic diagnostics and therapeutics, announced today that it has entered into a joint financing agreement (the "Agreement") with two Asia-based venture capital firms (the "New Investors"), pursuant to which BioLight and the New Investors will make a direct equity investment in BioLight's IOPtima Ltd. subsidiary via a private placement.

Previous Article
Seqirus announces FDA approval of Fluad for seasonal influenza
Seqirus announces FDA approval of Fluad for seasonal influenza

Seqirus announced today that the US Food and Drug Administration has approved Fluad (Influenza Vaccine, Adj...

Next Article
Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease
Impax's NUMIENT granted EC marketing authorization for symptomatic treatment of adult patients with Parkinson's disease

Impax Laboratories, Inc. today announced that the European Commission has granted marketing authorization f...